Abstract
Immunotherapy is one of the most promising therapeutic approaches in the field of cancer treatment. As a tumor progresses, tumor cells employ an array of immune-regulatory mechanisms to suppress immune responses within the tumor microenvironment. Using our understanding of these mechanisms, cancer immunotherapy has been developed to enhance the immune system’s effectiveness in treating cancer. Numerous cancer immunotherapies are currently in clinical use, yet many others are either in different stages of development or undergoing clinical studies. In this paper, we briefly discuss the features and current status of cancer immunotherapies. This includes the application of monoclonal antibodies, immune checkpoint inhibitors, adoptive cell therapy, cytokine therapy, cancer vaccines, and gene therapy, all of which have gained significant recognition in clinical practice. Additionally, we discuss limitations that may hinder successful clinical utilization and promising strategies, such as combining immunotherapy with nanotechnology. Graphical Abstract: (Figure presented.)
Original language | English |
---|---|
Article number | 168 |
Journal | AAPS PharmSciTech |
Volume | 25 |
Issue number | 6 |
DOIs | |
State | Published - Aug 2024 |
Bibliographical note
Publisher Copyright:© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024.
Funding
This work was supported by the Center for Pharmaceutical Research and Innovation (CPRI, NIH P20 GM130456), the National Center for Advancing Translational Sciences, and National Institutes of Health, through Grant UL1 TR001998 and R01NS136272. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funders | Funder number |
---|---|
Center for Pharmaceutical Research and Innovation, University of Kentucky | |
National Center for Advancing Translational Sciences (NCATS) | |
National Institutes of Health (NIH) | R01NS136272, P20 GM130456, UL1 TR001998 |
Keywords
- cancer immunotherapy
- combination therapy
- immunomodulation
ASJC Scopus subject areas
- Pharmaceutical Science